Although the deregulation of FGF/FGFR axis is known to play oncogenic roles in some tissue contexts, in others the FGFR activation reveals an opposite tumor suppressive outcome [3, 4]: this is the case of FGFR2, whose epithelial isoform FGFR2b/KGFR, controlled by the epithelial splicing regulatory proteins 1 and 2 (ESRP1 and ESRP2) [5] is down-regulated in several carcinomas [1, 3] and it has been proposed to exert a tumor suppressive role in vitro and in vivo [6, 7]. The gene discussed is ESRP2; the disease is neoplasm.